Evidence map›Paper›PMID 26699619›Full record

ArticlePloS one2015

Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.

Steffen B Wiegand, Benjamin Heidrich, Simone Susser, Magdalena Rogalska-Taranta, Jörg Petersen, Klaus H W Böker, Natalia Grigorian, Ralph Link, Uwe Naumann, Christine John and 6 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 1 country.

Steffen B WiegandDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Benjamin HeidrichDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Simone SusserDepartment of Internal Medicine I, University of Frankfurt, Frankfurt, Germany.
Magdalena Rogalska-TarantaDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Jörg PetersenIFI Institute for Interdisciplinary Medicine, Asklepios Klinik St Georg, Hamburg, Germany.
Klaus H W BökerMedical Practice, Hannover, Germany.
Natalia GrigorianDepartment of Internal Medicine II, University of Saarland, Saarland, Germany.
Ralph LinkDepartment of Internal Medicine, Clinic for Internal Medicine St. Josefs hospital, Offenburg, Germany.
Uwe NaumannCenter for Addiction-Medicine, Hepatology and HIV, Praxiszentrum Kaiserdamm, Berlin, Germany.
Christine JohnMedical Practice, Berlin, Germany.
Stefan LuethDepartment of Internal Medicine, University of Hamburg, Hamburg, Germany.
Peter MalfertheinerDepartment of Gastroenterology, Hepatology and Endocrinology, University of Magdeburg, Magdeburg, Germany.
Michael P MannsDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Heiner WedemeyerDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Christoph SarrazinGerman Liver Foundation, HepNet Study-House, Hannover and Frankfurt, Germany.
Markus CornbergDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Medizinische Hochschule Hannover · DEGerman Liver Foundation · DEGoethe University Frankfurt · DEAsklepios Klinik St. Georg · DEGerman Center for Infection Research · DEMSB Medical School Berlin · DESaarland University · DESt. Josefs Hospital · DEUniversität Hamburg · DEUniversity Hospital Magdeburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSNPs near the interferon lambda (IFNL) 3 gene are predictors for sustained virological response (SVR) in patients with chronic hepatitis C genotype (GT) 1. In addition, a dinucleotide frame shift in ss469415590 was described, which generates IFNL4. In this study, we compared the role of IFNL4 variants with IFNL3-(rs12979860) and IFNL3-(rs8099917) on response to pegylated (PEG)-IFN and Ribavirin (RBV) in patients with chronic hepatitis C GT2/3.

methodsWe recruited 1006 patients with chronic hepatitis C and GT2/3 in a large German registry. A treatment with PEG-IFN and Ribavirin was started by 959 patients. We performed genotyping of IFNL3 (rs12979860, n = 726; rs8099917, n = 687) and of IFNL4 (ss469415590; n = 631).

resultsBoth preferable IFNL3 genotypes were associated with RVR (both p<0.0001) rather than with SVR (rs12979860: p = 0.251; rs8099917: p = 0.447). Only RVR was linked to SVR in univariate and multivariate analyzes (both p<0.001). Concordance of genotyping in patients with available serum samples and EDTA blood samples (n = 259) was more than 96% for both IFNL3 SNPs. IFNL3-(rs12979860) correlated with IFNL4: 99.2% of patients with IFNL3-(rs12979860)-CC were IFNL4-(ss469415590)-TT/TT. IFNL3-(rs12979860)-CT was linked with IFNL4-(ss469415590)-TT/ΔG (98.0%) and IFNL3-(rs12979860)-TT was associated with IFNL4-(ss469415590)-ΔG/ΔG (97.6%).

conclusionIFNL3 genotyping from serum was highly efficient and can be used as an alternative if EDTA whole blood is not available. In Caucasian GT2/3 patients genotyping for INFL4-(ss469415590) does not lead to additional information for the decision-making process. Importantly, IFNL3 SNPs were not associated with SVR but with RVR. Even in the era of new direct acting antiviral (DAA) therapies, IFNL3 testing may therefore still be considered for naïve GT2/3 patients to decide if dual Peg-IFN/RBV therapy is an option in resource limited regions.

Indexed as

AdultAntiviral AgentsBiomarkersFemaleFollow-Up StudiesGenotypeHepacivirusHepatitis C, ChronicHumansInterferon LambdaInterferonsInterleukinsMalePolymorphism, Single NucleotidePrognosisProspective StudiesAntiviral AgentsBiomarkersIFNL4 protein, humanInterferon Lambdainterferon-lambda, humanInterferonsInterleukins

Identifiers

PMID26699619
PMCPMC4689517
OpenAlexW2225664703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.